Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday

Vaxart (OTCMKTS:VXRT) is expected to be posting its Q4 2025 resultson Thursday, March 12th. Analysts expect Vaxart to post earnings of ($0.08) per share and revenue of $35.95 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Vaxart Stock Up 8.3%

Shares of VXRT opened at $0.80 on Tuesday. The firm has a market cap of $192.48 million, a PE ratio of -3.48 and a beta of 1.17. The company’s fifty day moving average is $0.61 and its two-hundred day moving average is $0.45. Vaxart has a fifty-two week low of $0.26 and a fifty-two week high of $0.84.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $2.00.

Institutional Investors Weigh In On Vaxart

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart in the 1st quarter valued at approximately $31,000. Creative Planning bought a new position in Vaxart during the second quarter worth $33,000. Invesco Ltd. lifted its stake in Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp boosted its holdings in Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the period. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.